BeiGene
BGNE
$179.35
Share price
-0.29%
Change (1 day)
5.67%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
BeiGene (BGNE) - Cash on Hand
Cash on Hand as of June 2023 : $3.51 B
According to BeiGene
's latest financial reports the company has $3.51 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
BeiGene - Cash on Hand chart (from 2014 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2022-12-31 | $4.54 B | -31.47% |
| 2021-12-31 | $6.62 B | 42.2% |
| 2020-12-31 | $4.65 B | 372.73% |
| 2019-12-31 | $0.98 B | -45.53% |
| 2018-12-31 | $1.80 B | 116.02% |
| 2017-12-31 | $0.83 B | 127.48% |
| 2016-12-31 | $0.36 B | 266.39% |
| 2015-12-31 | $0.10 B | 126.35% |
| 2014-12-31 | $44.39 M | 1030.79% |
| 2013-12-31 | $3.92 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | $0.10 B | -96.93% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | $29.72 M | -99.15% | 🇺🇸 USA |